A study of a GLP-1 and GIP medicine, tirzepatide, in people with colorectal adenoma.
Recruiting now. Registry record last updated February 27, 2026.
- Who can join
- Adults 18 to 50, have colorectal adenoma, BMI 27+.
- What you take
- Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 3 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Colorectal Cancer Prevention. Also studied in: Colorectal Adenoma.
Full scientific study title: Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors.
Who can join
Adults 18 to 50, have colorectal adenoma, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Age 18-50 years Because no dosing or adverse event data are currently available on the use of tirzepatide in participants \<18 years of age, children are excluded from this study. Because we are specifically studying the prevention of EOCRC, which is defined as CRC occurring prior to age 50, the study population will only enroll participants under the age of 50 at baseline.
- BMI between 27 and 40 kg/m2
- Underwent a screening or surveillance colonoscopy within the prior 9 months.
- Removal of multiple (at least 2) colon or rectal adenomas (including sessile serrated adenomas but excluding hyperplastic polyps) or a single adenoma ≥6 mm in size during the last colonoscopy
- Ability to understand and the willingness to sign a written informed consent document.
Key exclusion criteria
- Participants who have ever taken incretin mimetic therapies.
- Participants with a history of medullary thyroid cancer or MEN 2 syndrome.
- Participants at high risk of pancreatitis or otherwise contraindicated for use of tirzepatide according to clinical labeling.
- Participants with a history of cancer (excluding non-melanoma skin) within the last three years
- Participants with a history of diabetes mellitus
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Massachusetts1 site
- Massachusetts General Hospital Cancer CenterBoston, Massachusetts
Timeline
Started enrolling: February 24, 2026. Expected completion: December 31, 2028. Last updated on ClinicalTrials.gov: February 27, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
